Tianyin to Attend 4th Annual OneMedForum San Francisco 2011 on January 10-13, 2011

CHENGDU, China, Dec. 1, 2010 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, has been invited to present at OneMedForum San Francisco 2011 on January 10-13, 2011 at Sir Francis Drake Hotel at 450 Powell Street, San Francisco, CA 94102.

Dr. James Jiayuan Tong, TPI's Chief Financial Officer, Chief Business & Development Officer and Board Director, was also invited to serve on the China Forum Advisory board and speak at a special China Forum educational seminar that is being organized prior to the OneMedForum in the afternoon of January 10.  

Dr. Tong will also deliver TPI's corporate presentation on January 11. For information about the OneMedForum, please visit www.onemedplace.com/forum

An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com

About OneMedForum

The OneMedForum San Francisco conference, launched in 2008, runs concurrently with J.P Morgan conference that provides an efficient access to the companies that shape the future of the rapidly changing healthcare landscape with company presentations, panels and workshops for strategic insights and practical benefits.

OneMedForum San Francisco 2011 dedicated a half-day China Forum seminar to help senior executives shape their strategies to approach what is one of the most lucrative and perilous markets in the world. They have assembled experts with experience in operating in the Healthcare sector as its advisory board and panelists.

OneMedTV, a division of OneMedPlace, will also cover the event to provide companies an efficient means to gain global exposure via digital distribution.

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. Tianyin currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. Tianyin has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about Tianyin, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.